Total Payments
$212,004
2024 Payments
$4,466
Companies
74
Transactions
1,080
Medicare Patients
3,264
Medicare Billing
$635,766
Payment Breakdown by Category
Other$93,154 (43.9%)
Research$41,925 (19.8%)
Consulting$26,796 (12.6%)
Food & Beverage$26,016 (12.3%)
Travel$23,211 (10.9%)
Education$903.01 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $93,154 | 26 | 43.9% |
| Unspecified | $41,925 | 3 | 19.8% |
| Consulting Fee | $26,796 | 7 | 12.6% |
| Food and Beverage | $26,016 | 909 | 12.3% |
| Travel and Lodging | $23,211 | 97 | 10.9% |
| Education | $903.01 | 38 | 0.4% |
Payments by Type
General
$170,079
1,077 transactions
Research
$41,925
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $141,742 | 220 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $42,257 | 19 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $5,052 | 61 | $0 (2024) |
| Aveo Pharmaceuticals, Inc. | $2,191 | 14 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,758 | 74 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,689 | 40 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,466 | 76 | $0 (2024) |
| Daiichi Sankyo Inc. | $1,148 | 44 | $0 (2024) |
| PFIZER INC. | $831.16 | 45 | $0 (2024) |
| Celgene Corporation | $814.84 | 35 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,466 | 157 | AstraZeneca Pharmaceuticals LP ($647.83) |
| 2023 | $6,796 | 167 | AVEO Pharmaceuticals, Inc. ($2,098) |
| 2022 | $5,888 | 192 | AstraZeneca Pharmaceuticals LP ($1,319) |
| 2021 | $54,084 | 108 | Rigel Pharmaceuticals, Inc. ($41,966) |
| 2020 | $19,179 | 85 | Incyte Corporation ($17,533) |
| 2019 | $31,311 | 139 | Incyte Corporation ($29,439) |
| 2018 | $30,043 | 125 | Incyte Corporation ($27,938) |
| 2017 | $60,238 | 107 | Incyte Corporation ($58,909) |
All Payment Transactions
1,080 individual payment records from CMS Open Payments — Page 1 of 44
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: BIOLOGIC | ||||||
| 12/15/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $22.43 | General |
| Category: Hematology/Oncology | ||||||
| 12/11/2024 | Fresenius Kabi USA, LLC | Stimufend (Biological) | Food and Beverage | In-kind items and services | $34.34 | General |
| Category: Biosimilars | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $34.22 | General |
| Category: Oncology | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $18.60 | General |
| Category: Oncology | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $20.71 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $25.37 | General |
| 11/19/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.66 | General |
| Category: Hematology | ||||||
| 11/15/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $11.63 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $25.08 | General |
| Category: Oncology | ||||||
| 11/14/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/11/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $10.27 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Oncology | ||||||
| 11/05/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: Oncology | ||||||
| 11/01/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $30.97 | General |
| Category: Hematology | ||||||
| 10/28/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $21.48 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.35 | General |
| Category: ONCOLOGY | ||||||
| 10/15/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $11.47 | General |
| Category: Hematology | ||||||
| 10/14/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| C-935788-057 | Rigel Pharmaceuticals, Inc. | $21,225 | 1 |
| C-935788-058 | Rigel Pharmaceuticals, Inc. | $20,700 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 812 | 1,951 | $520,101 | $134,640 |
| 2022 | 12 | 797 | 1,439 | $524,235 | $133,464 |
| 2021 | 12 | 809 | 1,914 | $656,658 | $173,342 |
| 2020 | 16 | 846 | 3,072 | $776,280 | $194,319 |
Total Patients
3,264
Total Services
8,376
Medicare Billing
$635,766
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 154 | 271 | $104,380 | $26,010 | 24.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 126 | 254 | $88,434 | $23,761 | 26.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 118 | 345 | $81,667 | $21,949 | 26.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 54 | 153 | $82,689 | $21,308 | 25.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 105 | 118 | $62,434 | $16,483 | 26.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 66 | 66 | $33,234 | $8,433 | 25.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 59 | 59 | $23,178 | $5,810 | 25.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 26 | 26 | $17,264 | $4,006 | 23.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 27 | 54 | $10,422 | $2,742 | 26.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 16 | 90 | $7,830 | $2,049 | 26.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 20 | 20 | $4,860 | $1,239 | 25.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 18 | $3,078 | $776.90 | 25.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 16 | 440 | $520.00 | $42.22 | 8.1% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 14 | 37 | $111.00 | $30.75 | 27.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 183 | 390 | $155,860 | $38,541 | 24.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 43 | 113 | $63,550 | $16,782 | 26.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 124 | 205 | $64,971 | $16,658 | 25.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 110 | 286 | $62,814 | $15,893 | 25.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 72 | 74 | $44,894 | $11,680 | 26.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 83 | 83 | $43,243 | $11,020 | 25.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 92 | 96 | $39,706 | $10,182 | 25.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 12 | 67 | $15,975 | $4,301 | 26.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 23 | 23 | $15,847 | $3,954 | 24.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 20 | 42 | $8,926 | $2,393 | 26.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 24 | 24 | $5,414 | $1,419 | 26.2% |
About Dr. John Knecht, MD
Dr. John Knecht, MD is a Medical Oncology healthcare provider based in Webster, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/05/2007. The National Provider Identifier (NPI) number assigned to this provider is 1639360829.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Knecht, MD has received a total of $212,004 in payments from pharmaceutical and medical device companies, with $4,466 received in 2024. These payments were reported across 1,080 transactions from 74 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($93,154).
As a Medicare-enrolled provider, Knecht has provided services to 3,264 Medicare beneficiaries, totaling 8,376 services with total Medicare billing of $635,766. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Internal Medicine
- Location Webster, TX
- Active Since 08/05/2007
- Last Updated 02/02/2026
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1639360829
Products in Payments
- JAKAFI (Drug) $132,872
- Tavalisse (Drug) $42,109
- CALQUENCE (Drug) $3,536
- FOTIVDA (Drug) $2,191
- KEYTRUDA (Biological) $1,317
- OPDIVO (Biological) $1,078
- ZEJULA (Drug) $773.16
- BLENREP (Biological) $767.02
- BRUKINSA (Drug) $678.49
- Enhertu (Drug) $556.28
- GILOTRIF (Drug) $492.80
- DARZALEX (Biological) $491.95
- IMBRUVICA (Drug) $487.75
- PADCEV (Biological) $378.05
- Pomalyst (Drug) $375.47
- BOSULIF (Drug) $354.66
- LIBTAYO (Biological) $354.65
- EPKINLY (Drug) $345.00
- IMFINZI (Biological) $316.15
- INJECTAFER (Drug) $299.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.